

2023 North Campus Antibioqram

GRAM NEGATIVE ORGANISMS						
Antibiogram 2023 North Campus	* Anaerobic coverage	Escherichia coli	Klebsiella (Enterobacter) aerogenes	Klebsiella pneumoniae	Proteus mirabilis	Pseudo. aeruginosa
# of isolates analyzed		954	32	211	94	64
		% Susceptible				
Amikacin						100%
Amoxicillin/Clavulanate	*	85%	0%	91%	100%	
Ampicillin	*	54%		0%	83%	
Ampicillin/Sulbactam	*	64%		81%	97%	
Cefazolin Uncomplicated UTI		85%		86%	98%	
Cefepime		92%	100%	87%	100%	95%
Ceftazidime		91%	81%	87%	100%	94%
Ceftriaxone		91%	81%	87%	100%	
Ceftolozane/tazobactam						98%
Ciprofloxacin		82%	97%	92%	84%	88%
Ertapenem	*	100%	100%	99%	100%	
Gentamicin		92%	100%	90%	96%	94%
Imipenem/Cilastatin	*	100%	89%	99%		91%
Levofloxacin		82%	97%	93%	86%	83%
Meropenem	*					91%
Nitrofurantoin		96%	31%	36%	0%	
Piperacillin /Tazobactam	*	97%	78%	92%	100%	94%
Tobramycin		92%	100%	92%	97%	100%
Trimethoprim-sulfa		78%	97%	86%	89%	

Organisms are reported when 30 or more are encountered per calendar year.

This antibiogram contains organisms isolated in 2022 and has been prepared from SCC SOFT LIS.

Only the first isolate per patient is included in the data per CLSI guidelines.

*Denotes activity against anaerobes. Anaerobes are not tested for susceptibility profiles at WakeMed.

** 11% of North MSSA isolates are positive for Clindamycin Inducible Resistance.

***2% of North MRSA isolates are positive for Clindamycin Inducible Resistance.

Resistant Organisms:

ESBL E. coli 80 isolates

ESBL K. pneumoniae 29 isolates

ESBL K. oxytoca 2 isolates

Carbapenem Resistant (CRE):

Klebsiella pneumoniae 1 isolate

Antibiograms are published annually for WakeMed Raleigh, WakeMed Cary and WakeMed North
by the Microbiology Lab and the Antimicrobial Stewardship Program. 919-350-8075

**WakeMed Health and Hospitals
Raleigh, NC**